Eli Lilly Cracks Down on Counterfeit Mounjaro Weight Loss and Diabetes Drugs, Sues Lawsuit Against Clinics
Portfolio Pulse from Vandana Singh
Eli Lilly has filed lawsuits against ten entities in the U.S., including medical spas, wellness centers, and compounding pharmacies, for selling unauthorized versions of its diabetes drug, Mounjaro. The lawsuits aim to prevent these entities from marketing the drug and seek unspecified monetary damages. This follows similar legal actions by Novo Nordisk against entities selling compounded versions of its weight-loss drugs. Eli Lilly's shares are up by 0.41% in the premarket session.
September 20, 2023 | 1:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's legal action against entities selling unauthorized versions of its drug Mounjaro could protect its market share and revenues. The news has had a positive impact on its premarket stock price.
The legal action taken by Eli Lilly is aimed at protecting its market share and revenues from the sale of its diabetes drug, Mounjaro. This news is likely to be viewed positively by investors, as reflected in the premarket stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Novo Nordisk has previously filed similar lawsuits against entities selling unauthorized versions of its weight-loss drugs. The mention of Novo Nordisk in this context is neutral.
Novo Nordisk is mentioned in the context of having previously taken similar legal action against entities selling unauthorized versions of its drugs. This mention does not have a direct impact on Novo Nordisk's stock price or business operations.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50